Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.
3 findings from 1 review
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Additional side effects of heparin · children with congenital heart disease undergoing CC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Heparin‐induced thrombocytopenia (HIT) · people undergoing surgical procedures and treated with UFH or LMWH for prophylaxis of thrombotic events lasting at least 5 days
The intervention may leads to lower heparin‐induced thrombocytopenia (HIT) (low certainty).
1 finding from 1 review
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in mortality attributable to hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review
Quality of life · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes frequency of adverse events ( compared with prostaglandin E1 (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).
1 finding from 1 review
Overall survival ( · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
It is very uncertain whether summary of findings: Heparin changes overall survival ( compared with no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia
Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).
1 finding from 1 review